LXRX Lexicon Pharmaceuticals, Inc.

bullish · high conviction SHIFT track record → $1.82 -0.01 (-0.6%)
Get emailed when LXRX changes direction
Mkt Cap $780M 52wk $0.51 - $1.95 Earnings 2026-05-12 2h ago
Insider buying: $2,722,625 bought by 19 insiders (30d)
Est. revisions: +0.0%
Factor Model (net +0.3)

Factor Model

net +0.3 1.2 / 10
Est. Revisions
+0.0
Insider Activity
+0.5
Momentum
+0.0
Analyst Rev.
+0.0
Narrative Gap
+0.0

Pilavapadin 10mg Cuts DPNP Pain in Phase 2b

Watch: Watch the April 22 presentation for detailed efficacy and safety data to gauge commercial viability and investor reaction.

Pilavapadin 10 mg showed nominally significant reduction in Average Pain at Week 8 for diabetic peripheral neuropathic pain in a Phase 2b study. The treatment was well tolerated with completion rates similar to placebo and few adverse event discontinuations. Lexicon will present these data on April 22, 2026, at the American Academy of Neurology Annual Meeting.

Positive Phase 2b results support pilavapadin's potential as a treatment in a challenging market, enhancing Lexicon's clinical pipeline and near-term visibility.

Evidence

3h ago Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data yahoo-finance
10d ago Insider buy by DEBBANE RAYMOND (LXRX): $2,980
10d ago Insider buy by DEBBANE RAYMOND (LXRX): $147,000
10d ago Insider buy by DEBBANE RAYMOND (LXRX): $219,755
10d ago Insider buy by DEBBANE RAYMOND (LXRX): $352,889
10d ago Insider buy by INVUS GLOBAL MANAGEMENT, LLC (LXRX): $2,000,001
33d ago H.C. Wainwright Remains a Buy on Alto Ingredients (ALTO) yahoo-finance
50d ago Proto Labs (PRLB) CFO gets new stock grants and tax-withholding share disposition - Stock Titan google-news-insider
1 older signals
60d ago Insider Purchase: Director at $LXRX Buys 100,000 Shares - Quiver Quantitative
Fundamentals & Data ▾
Lexicon Pharmaceuticals, Inc. Healthcare · Biotechnology
Mkt Cap
$780M
Beta
0.95
52w Range
$0.51 - $1.95
Short Interest
22.9M 10.67%
Days to Cover
8.6 -1%
Technicals downtrend
from 52w Hi
-2.7%
1w return
-2.1%
Insiders
buying 5B / 0S
EPS Estimate
$-0.04 +0.0% 30d 0up / 0dn
Est. Dispersion
114% 4 analysts
Analyst Target
$3 $1 - $6
Options P/C
0.05
Insider Cluster
buy cluster 2B / 0S
Fund Convergence
strong Citadel, Renaissance, Two Sigma
Financials
Revenue
$5M -79% YoY
FCF
$-17M
Gross Margin
96%
Op Margin
-269%
Momentum: decelerating
Top Holders
Citadel $3M
Renaissance
Two Sigma
Recent Filings & Data
insider trade 33
net buying · $2,722,625 bought
19 insiders · 33 transactions (30d)
Recent transactions
COIANTE SCOTT M · other
CRUM BRIAN T · other
DEFRANCESCO LISA · other
GRANOWITZ CRAIG B. M.D., PH.D. · other
MCDERMOTT WENDY · other
EXTON MICHAEL · other
MARTENS RACHEL YAP · other
GOPINATHAN SUMA · other
DEBBANE RAYMOND · buy · $2,980
DEBBANE RAYMOND · buy · $147,000
DEBBANE RAYMOND · buy · $219,755
DEBBANE RAYMOND · buy · $352,889
INVUS GLOBAL MANAGEMENT, LLC · award · $29,120,000
INVUS GLOBAL MANAGEMENT, LLC · buy · $2,000,001
SOBECKI CHRISTOPHER J · other
DEBBANE RAYMOND · other
SWAIN JUDITH L · other
BARKER SAMUEL L · other
AMOUYAL PHILIPPE · other
SULLIVAN DIANE E · other
CRUM BRIAN T · other
DEFRANCESCO LISA · other
GRANOWITZ CRAIG B. M.D., PH.D. · other
ALEXANDER KRISTEN · other
MAIN ALAN J · other
MCDERMOTT WENDY · other
ARTAL INTERNATIONAL S.C.A. · other
SOBECKI CHRISTOPHER J · other
LEFKOWITZ ROBERT J · other
DEBBANE RAYMOND · other
SWAIN JUDITH L · other
BARKER SAMUEL L · other
AMOUYAL PHILIPPE · other
9 signals · latest 3h ago

Get alerted when LXRX changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →